登入選單
返回Google圖書搜尋
The Challenges of the New EU Pharmaceutical Legislation
José Luis ValverdePaul Weissenberg
出版IOS Press, 2005
主題Business & Economics / Industries / Pharmaceutical & BiotechnologyLaw / GeneralLaw / Administrative Law & Regulatory PracticeLaw / Medical Law & LegislationLaw / Drugs & the LawMedical / Health PolicyMedical / PharmacyPolitical Science / GeneralPolitical Science / Public Policy / Health Care
ISBN15860352159781586035211
URLhttp://books.google.com.hk/books?id=zNEkPWlzpJUC&hl=&source=gbs_api
EBookSAMPLE
註釋In the domain of public policy on pharmaceuticals, protecting public health requires a dual strategy: robust regulation on the one hand and stimulation of competitiveness and innovation on the other. Regulation must be robust to ensure that only medicines meeting exact standards of safety, quality and efficacy are authorised for human and animal use. At the same time competitiveness and innovation must be stimulated. Without innovation in pharmaceuticals, the incurable diseases of today will remain incurable. Competitiveness drives innovation and innovation saves lives. Increased competitiveness of the pharmaceutical sector will not only better protect public health, but will also create high quality jobs and create growth. In this context the implementation of the G10 recommendations, particularly regarding the pricing and reimbursement of medicines by Member States, remains a considerable challenge.